A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects around 30% of the global population. Studies suggest ...

formerly known as non-alcoholic fatty liver disease (NAFLD)) is the most common and rapidly increasing cause of chronic liver disease worldwide, which can lead to liver cirrhosis and liver cancer via ...

HYDERABAD: We all know the importance of taking care of our mental health and heart, but what about our livers? Fatty liver ...

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...

This shows that a significant number of patients with non-alcohol-related cirrhosis had neuropathy and that the neuropathy was probably the effect of liver cirrhosis itself, rather than just being ...

Selvigaltin is a small molecule commercialized by Galecto, with a leading Phase II program in Decompensated Cirrhosis.

A new study finds that a blood test may be a more reliable indicator of liver disease than asking how much a person drinks.

The FDA has placed its most serious warning - called a Boxed Warning - on the non-hormonal drug fezolinetant, which is sold ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease ... which are linked to liver cirrhosis and other serious health ... Mechanism of Action ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...